MetaVia Inc
Research MetaVia Inc (MTVA) on Bullrun: market cap USD 10.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMTVA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 10.78M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 5.32M
- Free cash flow-USD 3.76M
Valuation Snapshot
latest market cap is USD 10.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 12.97M | -USD 15.70M | n/a | -7.35 | USD 10.28M | USD 210.00K | USD 5.33M |
| FY2024 | USD 0 | -USD 27.59M | -USD 24.72M | n/a | -39.13 | USD 16.02M | USD 136.00K | USD 7.93M |
| FY2023 | n/a | -USD 12.47M | -USD 10.85M | n/a | -2.46 | USD 22.44M | USD 203.00K | USD 16.69M |
| FY2022 | n/a | -USD 13.97M | n/a | n/a | -43.42 | USD 33.36M | n/a | USD 21.75M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 10.78M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 213.87M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 192.87M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 197.31M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 149.83M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 357.83M | n/a | n/a | n/a |
About MetaVia Inc
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is MetaVia Inc's market cap?
MetaVia Inc's market capitalization is USD 10.78M.
What does MetaVia Inc do?
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases.